 (Ji Clin Pathol 1996;49:230-232) 
Patients who receive multiple transfusions of blood components from a donor population unscreened for hepatitis C antibodies (anti-HCV) are at risk of developing post-transfusion hepatitis following infection with hepatitis C virus (HCV). Chronic hepatitis occurs in 50% of those infected with hepatitis C' and 20% of these develop cirrhosis within 10 The aim of this study was to establish the impact of hepatitis C infection on surviving patients, who were either treated for acute leukaemia or were BMT recipients before September 1991.
Methods
The study was conducted at Birmingham Heartlands Hospital, one of two adult BMT units serving the West Midlands. Each year about 15 new cases of acute leukaemia are seen and 25 BMTs (autologous and allogeneic) are carried out. We reviewed the records of all such patients who were treated prior to September 1991 and who are currently disease-free. The number of exposures to donor blood components was recorded. A donor exposure was defined as a single transfused unit of red cells, platelets, fresh frozen plasma, cryoprecipitate, or a platelet aphaeresis pack. Patients were recalled, and informed consent obtained before blood was taken to assess hepatitis C status and assay serum aspartate aminotransferase (AST) activities.
Anti-HCV screening was performed using a third generation enzyme linked immunosorbent assay (EIA, Ortho Diagnostics, Neckargemund, Germany). Reactive samples were further tested using a second EIA (Murex Diagnostics, Dartford, UK) and a recombinant immunoblot assay (RIBA-3, Ortho Diagnostics). All samples were also assessed by reverse transcriptase polymerase chain reaction (RT-PCR) for HCV RNA using the method of The prevalence of hepatitis C infection amongst multitransfused patients with haematological malignancy is low in this study. This is in contrast to both a recent Italian study where 29% (44/102) of children treated for acute lymphoblastic leukaemia were found to be hepatitis C positive6 and a Finnish study where 17% (12/71) of multitransfused adult patients with leukaemia were positive.7 The differences between countries seems to reflect the differing prevalence of hepatitis C in the local donor population. The quoted prevalence in Italy being 1-3%8 and in Finland 0-106%.6 These are both significantly higher than the prevalence of 0-028% found in the West Midlands. However, it is likely that the prevalence of hepatitis C carriage in blood donors was higher before 1985 when measures were introduced to prevent transmission of HIV via transfusion. 9 The frequency of anti-HCV anti-body in our study (4 8%) correlates with that found by Murphy et al (4-4%) in a group of 183 patients with leukaemia.'0 This is despite their use of a first generation assay, without confirmatory tests. Also, patients in that study were not long term survivors; seven of the eight hepatitis C positive patients had died of recurrent leukaemia.
Unlike previous studies61' we found no patients who were RT-PCR positive and anti-HCV negative. It is likely that immunocompromised patients with HCV will be anti-HCV antibody negative if tested while still immunosuppressed. However, they would be RNA positive by RT-PCR. It would be expected that, with time, teir immune systems would recover and anti-HCV be produced. As all of the patients in this study are long term survivors in remission we feel our results are consistent with this theory.
A look-back programme to identify patients who received blood components from known anti-HCV positive donors is underway in the UK.'2 Clearly, this programme will not detect patients who received blood from HCV positive donors who retired prior to the introduction of screening. Significantly, both HCV infected patients identified in this study were missed by the look-back programme.
Cirrhosis is likely to develop in around one fifth of patients with chronic hepatitis.2 Early identification of such patients is important as treatment with o-interferon can delay progression to cirrhosis; unfortunately, once cirrhosis is established interferon is of little benefit.'3 It is not possible to rely on raised serum aminotransferase activities alone to select patients for hepatitis C testing, as bot chronic infection and significant liver disease may be present in the absence of raised activities.'4 Most patients previously treated for acute leukaemia and BMT recipients are followed up indefinitely and are therefore readily accessible for testing. We therefore advocate screening of all such long term survivors for anti-HCV. These patients are at risk of developing life threatening complications of chronic hepatitis C infection many years after being cured of their original disease and, in the UK, the HCV look-back programme will not necessarily detect them. 
